Figure 2B,C illustrates the availability of EGFR genotyping since the tumor sampling in calendar days (Figure 2B) and working days (Figure 2C) from the point of view of patients (calendar days) and practitioners (working days), respectively. This evidence concerns the gene EGFR and neoplasm.